Compare Merck & Co., Inc. (MRK) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs PayPal Holdings, Inc. — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while PayPal Holdings, Inc. trades at $55.5 (market cap $47.07B). The key difference: Merck & Co., Inc. is far larger — about 7.5× PayPal Holdings, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and PayPal Holdings, Inc. for 106 Days on average.
| MRK | PYPL | |
|---|---|---|
Market Cap | $351.28B | $47.07B |
Volume | 7,969,665 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $156.43 | $75.75 |
52-Week Low | $82.49 | $39.08 |
Typical Hold Time | 98 Days | 106 Days |
Enterprise Value | $398.04B | $49.21B |
Dividend Yield | 2.39% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
PayPal (PYPL) trades at $55.47, up 0.95% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.4, net income margin of 14.36%, and consistent revenue growth from $33.17B in 2025 to $34.1B projected for 2026. Recent positive developments include a Meta partnership for AI-powered checkout and three consecutive quarterly earnings beats.
PYPL presents a compelling value opportunity with attractive valuation multiples and solid profitability, though investors face risks from checkout competition and slowing growth. Analyst consensus leans cautious with 60% hold ratings, but the $56.41 price target suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
